2024
Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract
Mao T, Kim J, Peña-Hernández M, Valle G, Moriyama M, Luyten S, Ott I, Gomez-Calvo M, Gehlhausen J, Baker E, Israelow B, Slade M, Sharma L, Liu W, Ryu C, Korde A, Lee C, Monteiro V, Lucas C, Dong H, Yang Y, Initiative Y, Gopinath S, Wilen C, Palm N, Dela Cruz C, Iwasaki A, Vogels C, Hahn A, Chen N, Breban M, Koch T, Chaguza C, Tikhonova I, Castaldi C, Mane S, De Kumar B, Ferguson D, Kerantzas N, Peaper D, Landry M, Schulz W, Grubaugh N. Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2319566121. PMID: 38648490, PMCID: PMC11067057, DOI: 10.1073/pnas.2319566121.Peer-Reviewed Original ResearchConceptsInterferon-stimulated genesRespiratory infectionsStrains of influenza A virusTreatment of respiratory viral infectionsRespiratory virus infectionsInfluenza A virusMouse model of COVID-19Respiratory viral infectionsNeomycin treatmentExpression of interferon-stimulated genesUpper respiratory infectionInterferon-stimulated gene expressionLower respiratory infectionsBroad spectrum of diseasesAdministration of neomycinRespiratory viral diseasesDisease to patientsUpper respiratory tractIntranasal deliveryCongenic miceIntranasal applicationNasal mucosaSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2A virusBeneficial and Detrimental Effects of Cytokines during Influenza and COVID-19
Chang D, Dela Cruz C, Sharma L. Beneficial and Detrimental Effects of Cytokines during Influenza and COVID-19. Viruses 2024, 16: 308. PMID: 38400083, PMCID: PMC10892676, DOI: 10.3390/v16020308.Peer-Reviewed Original ResearchConceptsDetrimental effects of cytokinesEffects of cytokinesSignaling moleculesUnfavorable outcomeMyriad processesPathological functionsCytokine effectsInflammatory cytokinesAntiviral cytokinesCytokinesViral infectionDisease severityPathological consequencesHomeostatic functionsOrganism deathDisease
2023
Editorial: Beneficial and pathological roles of myeloid cells during COVID-19
Sharma L, Sengupta S, Roger T. Editorial: Beneficial and pathological roles of myeloid cells during COVID-19. Frontiers In Immunology 2023, 14: 1194826. PMID: 37081868, PMCID: PMC10111195, DOI: 10.3389/fimmu.2023.1194826.Commentaries, Editorials and LettersCoronaviruses, Lysosomes, and Secondary Bacterial Infections: Coronaviruses Outsmart the Host
Peng X, Dela Cruz C, Sharma L. Coronaviruses, Lysosomes, and Secondary Bacterial Infections: Coronaviruses Outsmart the Host. DNA And Cell Biology 2023, 42: 189-193. PMID: 36763591, DOI: 10.1089/dna.2023.0002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSecondary bacterial infectionCellular homeostatic functionsHomeostatic functionsExtensive cell deathBacterial infectionsLysosomal lumenLysosomal machineryKey organellesLysosomal pathwayUnique adaptationsExit cellsSevere acute respiratory syndrome coronavirus 2Cell deathCellular componentsAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Pathogen killingCoronavirus disease 2019LysosomesLysosomal enzymesLysosomal environmentCoronavirus 2Host immunityCausative agent
2022
Coronavirus Lung Infection Impairs Host Immunity against Secondary Bacterial Infection by Promoting Lysosomal Dysfunction.
Peng X, Kim J, Gupta G, Agaronyan K, Mankowski MC, Korde A, Takyar SS, Shin HJ, Habet V, Voth S, Audia JP, Chang D, Liu X, Wang L, Cai Y, Tian X, Ishibe S, Kang MJ, Compton S, Wilen CB, Dela Cruz CS, Sharma L. Coronavirus Lung Infection Impairs Host Immunity against Secondary Bacterial Infection by Promoting Lysosomal Dysfunction. The Journal Of Immunology 2022, 209: 1314-1322. PMID: 36165196, PMCID: PMC9523490, DOI: 10.4049/jimmunol.2200198.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Bacterial infectionsMouse modelCoronavirus infectionLysosomal dysfunctionMajor health care challengeLung immune cellsLung tissue damageSecondary bacterial infectionImpair host immunityIL-1β releaseHealth care challengesCell deathPyroptotic cell deathBacterial killing abilityIL-1βBacterial clearanceImmune cellsSecondary infectionHost immunityAlveolar macrophagesTissue damageΒ-coronavirusStructural cellsCare challenges
2021
Cutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators
Schwarz B, Sharma L, Roberts L, Peng X, Bermejo S, Leighton I, Casanovas-Massana A, Minasyan M, Farhadian S, Ko AI, Team Y, Dela Cruz CS, Bosio CM. Cutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators. The Journal Of Immunology 2021, 206: ji2001025. PMID: 33277388, PMCID: PMC7962598, DOI: 10.4049/jimmunol.2001025.Peer-Reviewed Original ResearchConceptsLipid mediatorsRisk factorsSevere diseaseSevere SARS-CoV-2 infectionHospitalized COVID-19 patientsSARS-CoV-2 infectionImportant immune regulatory roleSevere COVID-19COVID-19 patientsImmune regulatory roleProinflammatory lipid mediatorsCOVID-19Immunomodulatory eicosanoidsImmune mediatorsSerum lipidomeAdvanced agePatientsCOVID-19 pandemicCytochrome P450MortalityDiseaseDysregulationMediatorsLMS productsLipidomeJAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis
Walz L, Cohen AJ, Rebaza AP, Vanchieri J, Slade MD, Dela Cruz CS, Sharma L. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. BMC Infectious Diseases 2021, 21: 47. PMID: 33430799, PMCID: PMC7797881, DOI: 10.1186/s12879-020-05730-z.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsType I interferonOdds of mortalityPositive clinical outcomesClinical outcomesI interferonICU admissionExcessive cytokine releaseType I interferon treatmentStandard treatment groupOdds of dischargeFavorable clinical outcomeNon-randomized trialsJanus kinase inhibitorSearch of MEDLINETerms of mortalityKinase inhibitor treatmentHospital dischargeCytokine releaseInterferon treatmentPotential antiviral candidatesNovel therapiesTreatment outcomesTreatment groupsAntiviral candidatesDisinfection of Pseudomonas aeruginosa from N95 respirators with ozone: a pilot study
Manning EP, Stephens MD, Dufresne S, Silver B, Gerbarg P, Gerbarg Z, Dela Cruz CS, Sharma L. Disinfection of Pseudomonas aeruginosa from N95 respirators with ozone: a pilot study. BMJ Open Respiratory Research 2021, 8: e000781. PMID: 33431507, PMCID: PMC7802653, DOI: 10.1136/bmjresp-2020-000781.Peer-Reviewed Original Research
2020
The kinetics of humoral response and its relationship with the disease severity in COVID-19
Ren L, Zhang L, Chang D, Wang J, Hu Y, Chen H, Guo L, Wu C, Wang C, Wang Y, Wang Y, Wang G, Yang S, Dela Cruz CS, Sharma L, Wang L, Zhang D, Wang J. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Communications Biology 2020, 3: 780. PMID: 33311543, PMCID: PMC7733479, DOI: 10.1038/s42003-020-01526-8.Peer-Reviewed Original ResearchConceptsHumoral responseDisease severityReceptor-binding domainAntibody titersSpike proteinSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2COVID-19Respiratory syndrome coronavirus 2Titers of NAbsGeometric mean titersCOVID-19 patientsSyndrome coronavirus 2Coronavirus disease 2019Disease courseMean titersCoronavirus 2Antibody responseIgG antibodiesRisk factorsIg levelsImmunoglobulin ADisease 2019Severe casesModerate infectionsIdentification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
Xiao X, Wang C, Chang D, Wang Y, Dong X, Jiao T, Zhao Z, Ren L, Dela Cruz CS, Sharma L, Lei X, Wang J. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2. Frontiers In Immunology 2020, 11: 586572. PMID: 33324406, PMCID: PMC7723961, DOI: 10.3389/fimmu.2020.586572.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Therapeutic agentsAnti-coronaviral activitySARS-CoV-2 drugsWide therapeutic windowCOVID-19 infectionNovel therapeutic agentsEffective compoundsTherapeutic optionsReplication of coronavirusesSafe drugSevere diseaseTherapeutic windowHuman coronavirusesTherapeutic candidateUS FDAArbidol hydrochlorideIdentification of PotentTwo-step screenMillions of peopleSafety indexDrugsCOVID-19 pandemicFDACoronavirusReply to Suri et al.: COVID-19 Real-Time RT-PCR: Does Positivity on Follow-up RT-PCR Always Imply Infectivity?
Chang D, Mo G, Yuan X, Tao Y, Peng X, Wang F, Xie L, Sharma L, Dela Cruz CS, Qin E. Reply to Suri et al.: COVID-19 Real-Time RT-PCR: Does Positivity on Follow-up RT-PCR Always Imply Infectivity? American Journal Of Respiratory And Critical Care Medicine 2020, 202: 148-148. PMID: 32401535, PMCID: PMC7328309, DOI: 10.1164/rccm.202004-1458le.Commentaries, Editorials and LettersPersistent Viral Presence Determines the Clinical Course of the Disease in COVID-19
Chang D, Zhao P, Zhang D, Dong JH, Xu Z, Yang G, Li BY, Liu HX, Li BA, Qin CF, Peng XH, Wang FS, Xie LX, Chen Z, Dela Cruz CS, Sharma L, Qin EQ. Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 2585-2591.e1. PMID: 32574840, PMCID: PMC7305869, DOI: 10.1016/j.jaip.2020.06.015.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBetacoronavirusC-Reactive ProteinChildChild, PreschoolComorbidityCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHumansInfantInflammationInflammation MediatorsInterleukin-6MaleMiddle AgedPandemicsPneumonia, ViralReal-Time Polymerase Chain ReactionRespiration, ArtificialSARS-CoV-2Severity of Illness IndexYoung AdultConceptsDisease severityViral clearanceViral persistenceDisease outcomeCOVID-19Viral presenceExtensive lung involvementC-reactive proteinEffective antiviral therapyCoronavirus disease 2019Severe disease outcomesHost antiviral mechanismsInfectious viral particlesImmunomodulatory therapyInflammatory markersLung involvementRespiratory supportClinical courseAntiviral therapyIL-6Viral reactivationClinical managementInflammatory responseChest imagingDisease 2019Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection
Chang D, Mo G, Yuan X, Tao Y, Peng X, Wang FS, Xie L, Sharma L, Dela Cruz CS, Qin E. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection. American Journal Of Respiratory And Critical Care Medicine 2020, 201: 1150-1152. PMID: 32200654, PMCID: PMC7193851, DOI: 10.1164/rccm.202003-0524le.Peer-Reviewed Original ResearchProfiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clinical Infectious Diseases 2020, 71: 778-785. PMID: 32198501, PMCID: PMC7184472, DOI: 10.1093/cid/ciaa310.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Humoral responseSymptom onsetIgM ELISAProbable casesEarly humoral responseHost humoral responseMajor healthcare threatCoronavirus disease 2019IgA antibody detectionCOVID-19Viral nucleic acidsQuantitative polymerase chain reactionNovel coronavirus diseaseFalse-negative resultsMedian durationAntibody testingIgG responsesIgM antibodiesInfected patientsPolymerase chain reactionPositive rateDisease 2019Healthcare threatSubclinical casesEpidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China
Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, Sharma L. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. JAMA 2020, 323: 1092-1093. PMID: 32031568, PMCID: PMC7042871, DOI: 10.1001/jama.2020.1623.Peer-Reviewed Original ResearchProtecting health-care workers from subclinical coronavirus infection
Chang D, Xu H, Rebaza A, Sharma L, Dela Cruz CS. Protecting health-care workers from subclinical coronavirus infection. The Lancet Respiratory Medicine 2020, 8: e13. PMID: 32061333, PMCID: PMC7128440, DOI: 10.1016/s2213-2600(20)30066-7.Commentaries, Editorials and Letters